
BIOTECH'S COMEBACK Why VCs are betting on "small data, big insights" – and leaving the genomics bubble behind
Three years ago, biotech was the hottest ticket in venture capital. Startups with names like Grail, Tempus, and 23andMe raised billions to sequence the world's DNA. The promise was intoxicating: big data would unlock the secrets of cancer, aging, and every rare disease. Investors threw money at anything with a sequencer and a cloud platform.








